JO3262B1 - توليفة من ديسيتابين مع مثبط سيتيدين دي أميناز واستخدامها في علاج السرطان - Google Patents
توليفة من ديسيتابين مع مثبط سيتيدين دي أميناز واستخدامها في علاج السرطانInfo
- Publication number
- JO3262B1 JO3262B1 JOP/2010/0108A JOP20100108A JO3262B1 JO 3262 B1 JO3262 B1 JO 3262B1 JO P20100108 A JOP20100108 A JO P20100108A JO 3262 B1 JO3262 B1 JO 3262B1
- Authority
- JO
- Jordan
- Prior art keywords
- decitabine
- combination
- cancer
- deamiase
- cytidine
- Prior art date
Links
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 title abstract 3
- 229960003603 decitabine Drugs 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 title 1
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 title 1
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000009615 deamination Effects 0.000 abstract 1
- 238000006481 deamination reaction Methods 0.000 abstract 1
- 230000002779 inactivation Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
يتعلق الاختراع الحالي بطرق لعلاج السرطان تشتمل على اعطاء ديسيتابين بالاشتراك مع مركبات تعمل على تثبيط نزع مجموعة الأمين للانزيم المسئول عن تثبيط ديسيتابين.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16711909P | 2009-04-06 | 2009-04-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
JO3262B1 true JO3262B1 (ar) | 2018-09-16 |
Family
ID=42357480
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JOP/2010/0108A JO3262B1 (ar) | 2009-04-06 | 2010-04-06 | توليفة من ديسيتابين مع مثبط سيتيدين دي أميناز واستخدامها في علاج السرطان |
Country Status (11)
Country | Link |
---|---|
US (1) | US8329666B2 (ar) |
EP (1) | EP2416780B1 (ar) |
JP (1) | JP5730854B2 (ar) |
AR (1) | AR076263A1 (ar) |
AU (1) | AU2010234641B2 (ar) |
CA (1) | CA2757744C (ar) |
ES (1) | ES2628580T3 (ar) |
JO (1) | JO3262B1 (ar) |
TW (1) | TWI503121B (ar) |
UY (1) | UY32546A (ar) |
WO (1) | WO2010118010A1 (ar) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JO2778B1 (ar) | 2007-10-16 | 2014-03-15 | ايساي انك | مركبات وتركيبات وطرق معينة |
WO2010118013A1 (en) * | 2009-04-06 | 2010-10-14 | Eisai Inc. | Combination of cytidine-based antineoplastic drugs with cytidine deaminase inhibitor and use thereof in the treatment of cancer |
TWI477508B (zh) * | 2009-04-06 | 2015-03-21 | Otsuka Pharma Co Ltd | 用以治療癌症之組成物及方法 |
US8609631B2 (en) | 2009-04-06 | 2013-12-17 | Eisai Inc. | Compositions and methods for treating cancer |
WO2017096357A1 (en) | 2015-12-03 | 2017-06-08 | Epidestiny, Inc. | Compositions containing decitabine, 5azacytidine and tetrahydrouridine and uses thereof |
CN110168092A (zh) | 2016-12-28 | 2019-08-23 | 特朗斯吉有限公司 | 溶瘤病毒和治疗分子 |
US11224610B2 (en) | 2018-09-19 | 2022-01-18 | Otsuka Pharmaceutical Co., Ltd. | Low dose combination CDA substrate drug/cedazuridine with extended administration |
EP3946322B1 (en) * | 2019-03-29 | 2023-09-20 | Novocure GmbH | Methods for restoring sensitivity to ttfields in ttfields-resistant cancer cells with ptger3 inhibitors |
US11938143B2 (en) | 2021-10-19 | 2024-03-26 | Akirabio, Inc. | Compositions comprising 2′-deoxycytidine analogs and use thereof for the treatment of sickle cell disease, thalassemia, and cancers |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4017606A (en) | 1973-10-04 | 1977-04-12 | The Upjohn Company | Organic compounds and process |
US4275057A (en) * | 1980-01-28 | 1981-06-23 | The United States Of America As Represented By The Department Of Health, Education And Welfare | Seven-membered ring compounds as inhibitors of cytidine deaminase |
US4526988A (en) | 1983-03-10 | 1985-07-02 | Eli Lilly And Company | Difluoro antivirals and intermediate therefor |
EP0160079B1 (en) | 1983-10-26 | 1990-01-31 | GREER, Sheldon B. | Method and materials for sensitizing neoplastic tissue to radiation |
IL77133A (en) * | 1984-12-04 | 1991-01-31 | Lilly Co Eli | Antineoplastic pharmaceutical compositions containing pentofuranoside derivatives,some new such compounds and their preparation |
US4965374A (en) | 1987-08-28 | 1990-10-23 | Eli Lilly And Company | Process for and intermediates of 2',2'-difluoronucleosides |
US5223608A (en) | 1987-08-28 | 1993-06-29 | Eli Lilly And Company | Process for and intermediates of 2',2'-difluoronucleosides |
US5968914A (en) | 1987-10-28 | 1999-10-19 | Pro-Neuron, Inc. | Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides |
WO1992018517A1 (en) | 1991-04-17 | 1992-10-29 | Yale University | Method of treating or preventing hepatitis b virus |
FR2682112B1 (fr) | 1991-10-08 | 1993-12-10 | Commissariat A Energie Atomique | Procede de synthese d'acide ribonucleique (arn) utilisant un nouveau reactif de deprotection. |
US5821357A (en) | 1992-06-22 | 1998-10-13 | Eli Lilly And Company | Stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoropurine and triazole nucleosides |
US5371210A (en) | 1992-06-22 | 1994-12-06 | Eli Lilly And Company | Stereoselective fusion glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides |
US5594124A (en) | 1992-06-22 | 1997-01-14 | Eli Lilly And Company | Stereoselective glycosylation process for preparing 2'-Deoxy-2',2'-difluoropyrimidine nucleosides and 2'-deoxy-2'-fluoropyrimidine nucleosides and intermediates thereof |
US5426183A (en) | 1992-06-22 | 1995-06-20 | Eli Lilly And Company | Catalytic stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides |
US5606048A (en) | 1992-06-22 | 1997-02-25 | Eli Lilly And Company | Stereoselective glycosylation process for preparing 2'-Deoxy-2', 2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides |
AU664948B2 (en) | 1993-02-23 | 1995-12-07 | City Of Hope | 4-ethoxy 5-fluoro 2'deoxyuridine |
AU6081294A (en) | 1993-05-14 | 1994-12-12 | Pro-Neuron, Inc. | Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides |
GB9311252D0 (en) | 1993-06-01 | 1993-07-21 | Hafslund Nycomed As | Cell growth regualtors |
US5637688A (en) | 1994-12-13 | 1997-06-10 | Eli Lilly And Company | Process for preparing 1-(2'-deoxy-2'-difluoro-d-ribofuranosyl)-4-aminopyrimidin-2-one hydrochloride |
US5521294A (en) | 1995-01-18 | 1996-05-28 | Eli Lilly And Company | 2,2-difluoro-3-carbamoyl ribose sulfonate compounds and process for the preparation of beta nucleosides |
US6001994A (en) | 1995-12-13 | 1999-12-14 | Eli Lilly And Company | Process for making gemcitabine hydrochloride |
US5760208A (en) | 1996-08-14 | 1998-06-02 | The Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations | Process to prepare pyrimidine nucleosides |
US6933287B1 (en) | 1999-03-01 | 2005-08-23 | Sheldon B. Greer | Dramatic simplification of a method to treat neoplastic disease by radiation |
DK1156827T3 (da) | 1999-03-01 | 2007-02-05 | Halogenetics Inc | Anvendelse af sammensætninger omfattende CldC som strålingssensibilisatorer ved behandlingen af neoplastiske sygdomme |
US6462191B1 (en) | 2000-07-13 | 2002-10-08 | Air Products And Chemicals, Inc. | Synthesis of 2-deoxy-2-fluoro-arabinose derivatives |
EP1348712B1 (en) | 2000-11-29 | 2011-05-04 | Mitsui Chemicals, Inc. | Processes and intermediates in the synthesis of L-thymidine |
EP1353693B1 (en) | 2001-01-16 | 2005-03-16 | Glaxo Group Limited | Pharmaceutical combination containing a 4-quinazolineamine and paclitaxel, carboplatin or vinorelbine for the treatment of cancer |
AU2002257446A1 (en) | 2001-05-18 | 2002-12-03 | Rakesh Kumar | Antiviral nucleosides |
EP1545558A4 (en) | 2002-09-24 | 2010-02-17 | Koronis Pharmaceuticals Inc | 1, 3, 5-TRIAZINES FOR THE TREATMENT OF VIRAL DISEASES |
WO2005115410A2 (en) | 2004-05-06 | 2005-12-08 | University Of Rochester | Context dependent inhibitors of cytidine deaminases and uses thereof |
WO2006015346A1 (en) | 2004-07-30 | 2006-02-09 | Pharmaessentia Corp. | STEREOSELECTIVE SYNTHESIS OF β-NUCLEOSIDES |
WO2006063105A1 (en) | 2004-12-08 | 2006-06-15 | Sicor Inc. | Difluoronucleosides and process for preparation thereof |
WO2008085611A2 (en) * | 2006-11-27 | 2008-07-17 | University Of Miami | Designer theraphy of pancreatic tumors |
WO2009021551A1 (en) | 2007-08-13 | 2009-02-19 | Universite De La Mediterranee | A method for assessing the risk of toxicity in a chemotherapy |
JO2778B1 (ar) | 2007-10-16 | 2014-03-15 | ايساي انك | مركبات وتركيبات وطرق معينة |
WO2010047698A1 (en) | 2008-10-22 | 2010-04-29 | University Of Alabama At Birmingham | Activation-induced cytidine deaminase inhibitor suppression of autoimmune diseases |
TWI477508B (zh) * | 2009-04-06 | 2015-03-21 | Otsuka Pharma Co Ltd | 用以治療癌症之組成物及方法 |
WO2010118013A1 (en) | 2009-04-06 | 2010-10-14 | Eisai Inc. | Combination of cytidine-based antineoplastic drugs with cytidine deaminase inhibitor and use thereof in the treatment of cancer |
-
2010
- 2010-04-06 UY UY0001032546A patent/UY32546A/es active IP Right Grant
- 2010-04-06 WO PCT/US2010/030078 patent/WO2010118010A1/en active Application Filing
- 2010-04-06 US US12/755,122 patent/US8329666B2/en active Active
- 2010-04-06 JO JOP/2010/0108A patent/JO3262B1/ar active
- 2010-04-06 EP EP10713755.6A patent/EP2416780B1/en active Active
- 2010-04-06 AR ARP100101143A patent/AR076263A1/es not_active Application Discontinuation
- 2010-04-06 JP JP2012504773A patent/JP5730854B2/ja active Active
- 2010-04-06 CA CA2757744A patent/CA2757744C/en active Active
- 2010-04-06 ES ES10713755.6T patent/ES2628580T3/es active Active
- 2010-04-06 TW TW099110582A patent/TWI503121B/zh active
- 2010-04-06 AU AU2010234641A patent/AU2010234641B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
EP2416780A1 (en) | 2012-02-15 |
AU2010234641B2 (en) | 2016-04-21 |
CA2757744A1 (en) | 2010-10-14 |
AR076263A1 (es) | 2011-06-01 |
WO2010118010A1 (en) | 2010-10-14 |
UY32546A (es) | 2010-10-29 |
JP5730854B2 (ja) | 2015-06-10 |
EP2416780B1 (en) | 2017-03-08 |
JP2012522841A (ja) | 2012-09-27 |
ES2628580T3 (es) | 2017-08-03 |
US8329666B2 (en) | 2012-12-11 |
TW201102072A (en) | 2011-01-16 |
CA2757744C (en) | 2018-02-13 |
US20100279967A1 (en) | 2010-11-04 |
AU2010234641A1 (en) | 2011-11-10 |
TWI503121B (zh) | 2015-10-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JO3262B1 (ar) | توليفة من ديسيتابين مع مثبط سيتيدين دي أميناز واستخدامها في علاج السرطان | |
UA107667C2 (uk) | Лікарські сполуки, що модулюють активність піруваткінази-м2, композиції на їх основі та застосування при лікуванні раку | |
TN2010000209A1 (en) | Treatment of uterine cancer and ovarian cancer with a parp inhibitor alone or in combination with anti-tumor agents | |
MY160041A (en) | Compositions and methods for treating parasitic infections | |
MX2009010066A (es) | Composiciones y metodos para la ablacion especifica de la evasion mutacional de terapias especificas para cancer. | |
MX2012006628A (es) | Microorganismos probioticos como agentes activos para mejorar el brillo de la piel. | |
EP2214495A4 (en) | NATURALLY PHOTODYNAMIC ACTIVE SUBSTANCES AND ITS USE | |
MY161237A (en) | Combination therapy comprising a cdk4/6 inhibitor and a p13k inhibitor for use in the treatment of cancer | |
AU2008232453A8 (en) | Methods and compositions for reduction of side effects of therapeutic treatments | |
MX2010006991A (es) | Tratamientos de cancer terapeuticos. | |
MX361467B (es) | Compuestos de isoindolina para uso en el tratamiento de cancer. | |
IL190796A0 (en) | Compositions and their uses for gene therapy of bone conditions | |
GB0920703D0 (en) | Compositions containing satiogens and methods of use | |
TN2010000208A1 (en) | Treatment of breast cancer with a parp inhibitor alone or in combination with anti-tumor agents | |
NI201200090A (es) | Composiciones para tratar náusea y vómito centralmente mediados | |
EP2173740A4 (en) | INHIBITORS OF HEMOXYGENASE AND THEIR USE IN THE TREATMENT OF CANCER AND DISEASES OF THE CENTRAL NERVOUS SYSTEM | |
TW200612918A (en) | Lonidamine analogs | |
MX2012000034A (es) | Metodos para el tratamiento o la prevencion de la fatiga. | |
MY150650A (en) | Pyrrolopyrimidine compounds and their uses | |
MX2012004741A (es) | Apremilast para el tratamiento de sarcoidosis. | |
TN2011000482A1 (en) | Organic compounds and their uses | |
TNSN08400A1 (en) | Organic compounds and their uses | |
IL207310A0 (en) | Vaccine compositions | |
WO2009114703A3 (en) | Combination therapy for the treatment of cancer | |
MX2012006629A (es) | Microorganismos probioticos como agentes activos contra cambios en microrelieve de la piel. |